Nebenwirkungen · Incresync
Incresync 12.5 mg/30 mg film-coated tablets Incresync 25 mg/30 mg film-coated tablets Incresync 25 mg/45 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 10
HOS-124699 · Präparat HOS-095913
Clinical studies conducted to support the efficacy and safety of Incresync involved the co-administration of alogliptin and pioglitazone as separate tablets. However, the results of bioequivalence studies have demonstrated that Incresync film-coated tablets are bioequivalent to the corresponding doses of alogliptin and pioglitazone co-administered as separate tablets.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-09-09T12:31:00Z · SHA-256 cbd1851f0d7bf897be948ef8b74484626964929eb5e4c45499b1be3f0ce7ae66 · Passage 407593190ee1ab80af26f7a9846da9e0a2649d723b890f0c4f027338962a3a00 · Zeichen 524–894 im Abschnitt